|
Is your compound
effective? Mechanism of effect? Proof-of-concept studies, drug
repositioning for new cardiovascular and metabolic disease (diabetes,
hyperlipidemia, obesity) indications? |
contact details |
References - We are proud of our present and previous partners:
Preclinical Research:
New methods, complex diseased animal models available (scroll down):
For references, see our Publications
| Evaluation of cardioprotective and/or antiarrhythmic compounds in myocardial ischemia/reperfusion or preconditioning in isolated rat and mouse heart models or in in vivo anesthetized rat models. | |
 |
Measurements: cardiac
function, infarct size, arrhythmias, enyzme release, high energy
phosphates, histomorphology, electrophysiology, biochemical analysis of
heart tissue and perfusate for any targets of your choice.
|
| Assessment of the antioxidant efficacy of cardiovascular drugs by means of direct detection of oxygen free radicals and nitric oxide with electron spin resonance spectroscopy in ischemia/reperfusion. | |
|
Measurements: oxygen free
radical production (electron resonance spectroscopy, HPLC), pro- and
antioxidant enzyme activities (SOD, GPX, CAT, NOS, XOR, NADH oxidases,
etc)
|
|
|
|
|
Measurements:
cardiac function in working
hearts isolated from rats subjected to in vivo coronary artery
occlusion, infarct size,
histomorphologic changes.
|
|
|
|
|
Measurements:
Measurements: NO (electron spin resonance spectroscopy), nitric oxide
synthase (NOS) activities, cGMP production, superoxide formation,
peroxynitrite formation (nitrotyrosine ELISA, immunohistochemistry), in
vitro peroxynitrite scavenger assays (dityrosine assay).
|
| Effects of cardioprotective compounds on myocardial ischemia, preconditioning, and vascular functions in hyperlipidemia/atherosclerosis (cholesterol-diet), nitrate-tolerance, and diabetes (STZ) models. | |
|
Measurements: plasma lipids,
cardiac function, infarct size, myocardial enzyme release,
histomorphologic changes, electrohpysiology, and any biochemical
parameters in rat and rabbit models of experimental
hypercholesterolemia, atherosclerosis, and nitrate-tolerance.
|
|
|
|
|
Measurements:
cardiac hsp mRNA and HSP protein contents after ischemia/reperfusion or
heat stress.
|
| Evaluation of matrix metalloproteinase (MMP) inhibitors. | |
|
Measurements:
MMP and TIMP activities and protein contens in vivo and ex vivo. In
vitro MMP inhibition assays.
|